Targeted anti-mitotic therapies: can we improve on tubulin agents? (original) (raw)

• Wood, K. W. et al. Past and future of the mitotic spindle as an oncology target. Curr. Opin. Pharmacol. 1, 370–377 (2001).
  Article CAS PubMed Google Scholar
• Nigg, E. A., Blangy, A. & Lane, H. A. Dynamic changes in nuclear architecture during mitosis: on the role of protein phosphorylation in spindle assembly and chromosome segregation. Exp. Cell Res. 229, 174–180 (1996).
  Article CAS PubMed Google Scholar
• Keen, N. & Taylor, S. Aurora-kinase inhibitors as anticancer agents. Nature Rev. Cancer 4, 927–936 (2004).
  Article CAS Google Scholar
• Strebhardt, K., Ullrich, A., Authors, F. N. & Ullrich, A. Targeting polo-like kinase 1 for cancer therapy. Nature Rev. Cancer 6, 321–330 (2006).
  Article CAS Google Scholar
• Blangy, A. et al. Phosphorylation by p34cdc2 regulates spindle association of human Eg5,a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 83, 1159–1169 (1995).
  Article CAS PubMed Google Scholar
• Schaar, B. T. et al. CENP-E function at kinetochores is essential for chromosome alignment. J. Cell Biol. 139, 1373–1382 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Wood, K. W. et al. CENP-E is a plus end-directed kinetochore motor required for metaphase chromosome alignment. Cell 91, 357–366 (1997).
  Article CAS PubMed Google Scholar
• Abrieu, A. et al. CENP-E as an essential component of the mitotic checkpoint in vitro. Cell 102, 817–826 (2000). This thought-provoking study shows the crucial role of CENPE in mitotic-spindle checkpoint regulation in addition to its previously known role in chromosome alignment.
  Article CAS PubMed Google Scholar
• Tao, W. et al. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell 8, 49–59 (2005). This study shows that mitotic arrest alone can be insufficient to cause tumour cell death, and that subsequent events ultimately define cell fate.
  Article CAS PubMed Google Scholar
• Jordan, M. A. et al. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res. 56, 816–825 (1996).
  CAS PubMed Google Scholar
• Marcus, A. I. et al. Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and-sensitive cancer cells. J. Biol. Chem. 280, 11569–11577 (2005).
  Article CAS PubMed Google Scholar
• Castedo, M. et al. Cell death by mitotic catastrophe: a molecular definition. Oncogene 23, 2825–2837 (2004).
  Article CAS PubMed Google Scholar
• Michel, L. et al. Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation and mitotic failure in human somatic cells. Proc. Natl Acad. Sci. USA 101, 4459–4464 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Kops, G. J. P. L., Foltz, D. R. & Cleveland, D. W. Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc. Natl Acad. Sci. USA 101, 8699–8704 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Michel, L., Benezra, R. & Diaz-Rodriguez, E. A double edged sword: MAD2 dependent mitotic checkpoint defects in tumorigenesis and tumor cell death. Cell Cycle 3, 990–992 (2006).
  Google Scholar
• Ditchfield, C. et al. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J. Cell Biol. 161, 267–280 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Kashina, A. S. et al. The bimC family of kinesins: essential bipolar mitotic motors driving centrosome separation. Biochimica Biophysica Acta 1357, 257–271 (1997).
  Article CAS Google Scholar
• Hegde, P. S. et al. Differential gene expression analysis of kinesin spindle protein in human solid tumors. Proc. Am. Soc. Clin. Oncol. 22, 535 (2003).
  Google Scholar
• Mayer, T. U. et al. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 286, 971–974 (1999). The first study to show that selective inhibitors of KSP could be identified and shown to have excellent anti-mitotic activity
  Article CAS PubMed Google Scholar
• Sakowicz, R. et al. Antitumor activity of a kinesin inhibitor. Cancer Res. 64, 3276–3280 (2004).
  Article CAS PubMed Google Scholar
• Brier, S. et al. Identification of the protein binding region of S-trityl-L-cysteine, a new potent inhibitor of the mitotic kinesin Eg5. Biochemistry 43, 13072–13082 (2004).
  Article CAS PubMed Google Scholar
• Debonis, S. et al. In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities. Mol. Cancer Ther. 3, 1079–1090 (2004).
  CAS PubMed Google Scholar
• Gartner, M. et al. Development and biological evaluation of potent and specific inhibitors of mitotic Kinesin Eg5. Chembiochem. 6, 1173–1177 (2005).
  Article CAS PubMed Google Scholar
• Sunder-Plassmann, N. et al. Synthesis and biological evaluation of new tetrahydro-beta-carbolines as inhibitors of the mitotic kinesin Eg5. Bioorg. Med. Chem. 13, 6094–6111 (2005).
  Article CAS PubMed Google Scholar
• Cox, C. D. et al. Kinesin spindle protein (KSP) inhibitors. Part 1: the discovery of 3, 5-diaryl-4, 5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP. Bioorg. Med. Chem. Lett. 15, 2041–2045 (2005).
  Article CAS PubMed Google Scholar
• Yan, Y. et al. Inhibition of a mitotic motor protein: where, how, and conformational consequences. J. Mol. Biol. 335, 547–554 (2004).
  Article CAS PubMed Google Scholar
• Johnson, R. K. et al. SB-715992, a potent and selective inhbitor of the mitotic kinesin KSP, demonstrates broad-spectrum activity in advanced murine tumors and human tumor xenografts. Proc. Am. Assoc. Can. Res. 43, 269 (2002).
  Google Scholar
• Gonzales, P. et al. Breadth of anti-tumor activity of CK0238273 (SB-715992), a novel inhibitor of the mitotic kinesin KSP. Proc. Am. Assoc. Can. Res. 43, 269 (2002).
  Google Scholar
• Lobell, R. B. et al. In vivo characterization of an inhibitor of the mitotic kinesin, KSP: pharacodynamics, efficacy, and tolerability in xenograft tumor models. Proc. AACR-NCI-EORTC Mol. Tar. Can. Ther. Mtg Abst. B 189 (2005).
• Garcia-Saez, I. et al. Crystal structure of the motor domain of the human kinetochore protein CENP-E. J. Mol. Biol. 340, 1107–1116 (2004).
  Article CAS PubMed Google Scholar
• Liu, D. et al. Interaction of Skp1 with CENP-E at the midbody is essential for cytokinesis. Biochem. Biophys. Res. Comm. 345, 394–402 (2006).
  Article CAS PubMed Google Scholar
• Yao, X. et al. The microtubule-dependent motor centromere-associated protein E (CENP-E) is an integral component of kinetochore corona fibers that link centromeres to spindle microtubules. J. Cell Biol. 139, 435–447 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Chan, G. K. et al. Human BUBR1 is a mitotic checkpoint kinase that monitors CENP-E functions at kinetochores and binds the cyclosome/APC. J. Cell Biol. 146, 941–954 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Mao, Y. et al. Activating and silencing the mitotic checkpoint through CENP-E-dependent activation/inactivation of BubR1. Cell 114, 87–98 (2003).
  Article CAS PubMed Google Scholar
• McEwen, B. F. et al. CENP-E is essential for reliable bioriented spindle attachment, but chromosome alignment can be achieved via redundant mechanisms in mammalian cells. Mol. Biol. Cell 12, 2776–2789 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Yao, X. et al. CENP-E forms a link between attachment of spindle microtubules to kinetochores and the mitotic checkpoint. Nature Cell Biol. 2, 484–491 (2000).
  Article CAS PubMed Google Scholar
• Kapoor, T. M. et al. Chromosomes can congress to the metaphase plate before biorientation. Science 311, 388–391 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Putkey, F. R. et al. Unstable kinetochore-microtubule capture and chromosomal instability following deletion of CENP-E. Dev. Cell 3, 351–365 (2002).
  Article CAS PubMed Google Scholar
• Andrews, P. D., Knatko, E., Moore, W. J. & Swedlow, J. R. Mitotic mechanics: the auroras come into view. Curr. Opin. Cell Biol. 15, 672–683 (2003).
  Article CAS PubMed Google Scholar
• Marumoto, T., Zhang, D. & Saya, H. Aurora-A- a guardian of poles. Nature Rev. Cancer 5, 42–50 (2005).
  Article CAS Google Scholar
• Matthews, N., Visintin, C., Hartzoulakis, B., Jarvis, A. & Selwood, D. L. Aurora A and B kinases as targets for cancer: will they be selective for tumors? Expert Rev. Anticancer Ther. 6, 109–120 (2006).
  Article CAS PubMed Google Scholar
• Ecsedy, J. A. et al. Effect of aurora A inhibition in cultured human tumor cells using the selective small molecule inhibitor MLN8054. AACR Meeting Abstracts 2006 488 (2006).
  Google Scholar
• Giet, R. et al. Drosophila Aurora A kinase is required to localize D-TACC to centrosomes and to regulate astral microtubules. J. Cell Biol. 156, 437–451 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Hannak, E., Kirkham, M., Hyman, A. A. & Oegema, K. Aurora-A kinase is required for centrosome maturation in Caenorhabditis elegans. J. Cell Biol. 155, 1109–1116 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Adams, R. R., Maiato, H., Earnshaw, W. C. & Carmena, M. Essential roles of Drosophila inner centromere protein (INCENP) and aurora B in histone H3 phosphorylation, metaphase chromosome alignment, kinetochore disjunction, and chromosome segregation. J. Cell Biol. 153, 865–880 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Hauf, S. et al. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J. Cell Biol. 161, 281–294 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Gizatullin, F. et al. The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res. 66, 7668–7677 (2006).
  Article CAS PubMed Google Scholar
• Yang, H. et al. Mitotic requirement for aurora A kinase is bypassed in the absence of aurora B kinase. FEBS Lett. 579, 3385–3391 (2005).
  Article CAS PubMed Google Scholar
• Hoover, R. R. & Harding, M. W. Synergistic activity of the aurora kinase inhibitor MK-0457 (VX-680) with idarubicin, Ara-C, and inhibitors of BCR-ABL. ASH Annual Meeting Abstracts 108, 1384 (2006).
  Google Scholar
• Barr, F. A., Sillje, H. H. W. & Nigg, E. A. Polo-like kinases and the orchestration of cell division. Nature Rev. Mol. Cell Biol. 5, 429–440 (2004).
  Article CAS Google Scholar
• Takai, N., Hamanaka, R., Yoshimatsu, J. & Miyakawa, I. Polo-like kinases (Plks) and cancer. Oncogene 24, 287–291 (2005).
  Article CAS PubMed Google Scholar
• Eckerdt, F., Yuan, J. & Strebhardt, K. Polo-like kinases and oncogenesis. Oncogene 24, 267–276 (2005).
  Article CAS PubMed Google Scholar
• Sumara, I. et al. Roles of polo-like kinase 1 in the assembly of functional mitotic spindles. Curr. Biol. 14, 1712–1722 (2004).
  Article CAS PubMed Google Scholar
• Liu, X. Q. & Erikson, R. L. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc. Natl Acad. Sci. USA 100, 5789–5794 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Chu, Q. S. et al. Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV Q 21 days. J. Clin. Oncol. 22, 2078 (2004).
  Article Google Scholar
• Chu, Q. S. et al. A phase I study to determine the safety and pharmacokinetics of IV administered SB-715992, a novel kinesin spindle protein (KSP) inhibitor, in patients (pts) with solid tumors. Proc. Am. Soc. Clin. Oncol. 22, 525 (2003).
  Google Scholar
• Burris, H. A. et al. Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV days 1, 8, 15 q 28 days. J. Clin. Oncol. 22, 2004 (2004).
  Article Google Scholar
• Miller, K. et al. Phase II, open label study of SB-715992 (ispinesib) in subjects with advanced or metastatic breast cancer. San Antonio Breast Cancer Symp. abst. 1089 (2005).
• Jackson, J. R. et al. A second generation KSP inhibitor, SB-743921, is a highly potent and active therapeutic in preclinical models of cancer. AACR Meeting Abstracts 2006, B11 (2006).
  Google Scholar
• Holen, K. D. et al. Phase I study to determine tolerability and pharmacokinetics (PK) of SB-743921, a novel kinesin spindle protein (KSP) inhibitor. J. Clin. Oncol. 24, 2000 (2006).
  Google Scholar
• Holen, K. D. et al. Phase I study to determine tolerability and pharmacokinetics (PK) of SB-743921, a novel kinesin spindle protein (KSP) inhibitor. J. Clin. Oncol. 23, 2010 (2005).
  Article Google Scholar
• Stein, M. N. et al. Phase I clinical and pharmacokinetic (PK) trial of the kinesin spindle protein (KSP) inhibitor MK-0731 in cancer patients. J. Clin. Oncol. 24, 2001 (2006).
  Article Google Scholar
• Rubin, E. H. et al. A phase I clinical and pharmacokinetic (PK) trial of the aurora kinase (AK) inhibitor MK-0457 in cancer patients. J. Clin. Oncol. 24, 3009 (2006).
  Google Scholar
• Schellens, J. H. et al. Phase I and pharmacological study of the novel aurora kinase inhibitor AZD1152. J. Clin. Oncol. 24, 3008 (2006).
  Google Scholar
• Hofheinz, R. et al. A phase I repeated dose escalation study of the Polo-like kinase 1 inhibitor BI 2536 in patients with advanced solid tumours. J. Clin. Oncol. 24, 2038 (2006).
  Article Google Scholar
• Munzert, G. et al. A phase I study of two administration schedules of the Polo-like kinase 1 inhibitor BI 2536 in patients with advanced solid tumors. J. Clin. Oncol. 24, 3069 (2006).
  Article Google Scholar
• Ohnuma, T. et al. Phase I study of ON 01910. Na by 3-day continuous infusion (CI) in patients (pts) with advanced cancer. J. Clin. Oncol. 24, 13137 (2006).
  Google Scholar
• Donehower, R. C. et al. Phase I study of ON-01910. Na, a novel cell cycle inhibitor in adult patients with solid tumors. J. Clin. Oncol. 24, 13026 (2006).
  Google Scholar
• Steegmaier, M. et al. BI 2536, a potent and highly selective inhibitor of Polo-like kinase 1 (Plk1), induces mitotic arrest and apoptosis in a broad spectrum of tumor cell lines. Clin. Cancer Res. 11, 9147 (2005).
  Google Scholar
• Cogswell, J. P., Brown, C. E., Bisi, J. E. & Neill, S. D. Dominant-negative polo-like kinase 1 induces mitotic catastrophe independent of cdc25C function. Cell Growth Differ. 11, 615–623 (2000).
  CAS PubMed Google Scholar
• Soncini, C. et al. PHA-680632, a novel aurora kinase inhibitor with potent antitumoral activity. Clin. Cancer Res. 12, 4080–4089 (2006).
  Article CAS PubMed Google Scholar
• Chang, J. C. et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362, 362–369 (2003). This landmark study showed that gene-expression profiles from patient tumour samples can predict whether the disease will respond to taxane therapy.
  Article CAS PubMed Google Scholar
• Gianni, L. et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J. Clin. Oncol. 23, 7265–7277 (2005).
  Article CAS PubMed Google Scholar
• Komatsu, M. et al. Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers. Mol. Cancer Ther. 5, 767–775 (2006).
  Article CAS PubMed Google Scholar
• Magne, N., Largillier, R., Marcy, P. Y., Magne, J. & Namer, M. Cardiac toxicity assessment in locally advanced breast cancer treated neoadjuvantly with doxorubicin/paclitaxel regimen. Supp. Care Cancer 13, 819–825 (2005).
  Article Google Scholar
• Holmes, F. A. et al. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase i study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J. Clin. Oncol. 14, 2713–2721 (1996).
  Article CAS PubMed Google Scholar
• Mondesire, W. H. et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin. Cancer Res. 10, 7031–7042 (2004).
  Article CAS PubMed Google Scholar
• Kenny, L. M. et al. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res. 65, 10104–10112 (2005).
  Article CAS PubMed Google Scholar
• Kenny, L. M. et al. Early assessment of response to treatment in breast cancer by [18F]fluorothymidine-positron emission tomography. J. Clin. Oncol. (Meeting Abstracts) 23, 2084 (2005).
  Google Scholar
• Cleveland, D. W., Mao, Y. & Sullivan, K. F. Centromeres and kinetochores: from epigenetics to mitotic checkpoint signaling. Cell 112, 407–421 (2003).
  Article CAS PubMed Google Scholar